Beijing Jingshi Weikang Pharmaceutical Technology

Beijing Jingshi Weikang Pharmaceutical Technology is a Chinese biotechnology company founded in 2003, specializing in the research and development of modern Traditional Chinese Medicine (TCM) and natural products. The company primarily focuses on respiratory health, with its lead candidate, Aiqin Zhike Granules, having reached Phase 2b clinical trials for the treatment of acute tracheitis and bronchitis. Headquartered in Beijing, the company leverages expertise in herbal formulations to develop innovative therapies for inflammatory and infectious respiratory conditions. Its business scope encompasses technology development, transfer, and medical research and experimental development, often collaborating with prominent Chinese medical institutions for clinical validation.